Unicorn Alert: This Strange Gas Poses a HUGE Problem For Semiconductors…
This odorless, colorless gas is critical for every piece of technology you own. However, the world's supply is running dangerously low. That's why this one company could explode over 2021.
Click Here To See This Incredibly Valuable Gas

PCSA Insider Trading (Processa Pharmaceuticals)

Insider Ownership Percentage: 25.70%
Insider Buying (Last 12 Months): $121,650.00
Insider Selling (Last 12 Months): $5,077,490.85

Processa Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Processa Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Processa Pharmaceuticals Share Price & Price History

Current Price: $7.13
Price Change: Price Decrease of -0.29 (-3.91%)
As of 10/19/2021 01:32 PM ET

This chart shows the closing price history over time for PCSA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Seattle Cannabis Company Capitalizes on Surging Demand
The increase in the number of states that permit recreational and medical use of cannabis means that growers, processors and manufacturers of cannabis products often can't keep up with growing demand. One Seattle weed manufacturer is poised to sell products across state lines, easing shortages. This could drive the company's shares sky-high.
Get all the details on this potential blockbuster!

Processa Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/26/2021Patrick LinInsiderBuy4,000$6.02$24,080.00422,890View SEC Filing Icon  
6/23/2021David YoungCEOBuy10,000$7.67$76,700.00345,190View SEC Filing Icon  
6/22/2021Robert Michael FloydCOOBuy2,000$7.03$14,060.0028,000View SEC Filing Icon  
6/21/2021James H. StankerCFOBuy1,000$6.81$6,810.0036,510View SEC Filing Icon  
4/13/2021Justin W. YorkeDirectorSell6,500$9.86$64,090.00300,706View SEC Filing Icon  
4/13/2021Justin W. YorkeDirectorSell6,500$9.86$64,090.00300,706View SEC Filing Icon  
4/8/2021James E BesserInsiderSell400,000$10.76$4,304,000.001,064,300View SEC Filing Icon  
4/6/2021James E BesserInsiderSell31,771$10.91$346,621.611,064,300View SEC Filing Icon  
2/22/2021James E BesserMajor ShareholderSell20,929$11.56$241,939.241,120,000View SEC Filing Icon  
2/18/2021James E BesserMajor ShareholderSell5,000$11.35$56,750.001,120,000View SEC Filing Icon  
10/2/2020James E BesserMajor ShareholderBuy30,000$4.04$121,200.00405,000View SEC Filing Icon  
See Full Table
Insider Buying at Processa Pharmaceuticals?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Processa Pharmaceuticals and related companies.

SEC Filings (Institutional Ownership Changes) for Processa Pharmaceuticals (NASDAQ:PCSA)

8.78% of Processa Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at PCSA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Processa Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/17/2021Millennium Management LLC54,154$0.44M0.0%-42.4%0.348%Search for SEC Filing on Google Icon
8/17/2021Citadel Advisors LLC10,106$83K0.0%-23.0%0.065%Search for SEC Filing on Google Icon
8/16/2021State Street Corp16,600$0.14M0.0%N/A0.107%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC37,400$0.31M0.0%+34.4%0.240%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.373,171$3.06M0.0%+136.7%2.397%Search for SEC Filing on Google Icon
8/10/2021Coastal Bridge Advisors LLC27,500$0.23M0.0%+37.5%0.177%Search for SEC Filing on Google Icon
8/9/2021Vectors Research Management LLC4,000$33K0.0%N/A0.026%Search for SEC Filing on Google Icon
5/21/2021Citadel Advisors LLC13,117$0.14M0.0%N/A0.085%Search for SEC Filing on Google Icon
5/19/2021Worth Venture Partners LLC90,968$0.94M0.5%N/A0.586%Search for SEC Filing on Google Icon
5/18/2021Millennium Management LLC93,999$1.03M0.0%-12.0%0.606%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC13,117$0.14M0.0%N/A0.085%Search for SEC Filing on Google Icon
5/17/2021Coastal Bridge Advisors LLC20,000$0.22M0.0%N/A0.129%Search for SEC Filing on Google Icon
5/12/2021Northern Trust Corp12,845$0.14M0.0%N/A0.083%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC27,825$0.30M0.0%N/A0.179%Search for SEC Filing on Google Icon
5/12/2021Essex Investment Management Co. LLC72,908$0.80M0.1%-2.7%0.470%Search for SEC Filing on Google Icon
5/4/2021Commonwealth Equity Services LLC10,550$0.12M0.0%N/A0.068%Search for SEC Filing on Google Icon
4/27/2021Janney Montgomery Scott LLC63,331$0.69M0.0%-4.5%0.408%Search for SEC Filing on Google Icon
2/13/2021Essex Investment Management Co. LLC74,928$0.49M0.1%N/A0.709%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Processa Pharmaceuticals logo
Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its lead product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Hanover, MD.
Read More on Processa Pharmaceuticals

Today's Range

Now: $7.13
Low: $7.07
High: $7.16

50 Day Range

MA: $7.03
Low: $5.28
High: $8.57

52 Week Range

Now: $7.13
Low: $4.05
High: $14.24

Volume

306 shs

Average Volume

75,674 shs

Market Capitalization

$111.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.31

Who are the company insiders with the largest holdings of Processa Pharmaceuticals?

Processa Pharmaceuticals' top insider investors include:
  1. James E Besser (Major Shareholder)
  2. James E Besser (Insider)
  3. Patrick Lin (Insider)
  4. David Young (CEO)
  5. Justin W Yorke (Director)
  6. James H Stanker (CFO)
  7. Robert Michael Floyd (COO)
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors
According to Bloomberg NEF, changing the world to "All Green Energy" could cost about $173 trillion. And without this rare metal, going green would be IMPOSSIBLE. That's why there's a literal "gold rush" to find it. (HINT: It's not electric vehicles, nuclear power, or wind energy).
Show Me How This Industry Could Explode!